BioCentury | May 9, 2018
Distillery Therapeutics

Dermatology

...in mouse models of other types of palmoplantar keratoderma and other diseases involving hyperproliferative keratinocytes. Evgen Pharma plc...
BioCentury | Jan 18, 2017
Clinical News

SFX-01: Ph II STEM started

...tamoxifen or a third-generation aromatase inhibitor in about 60 patients with evidence of disease progression. Evgen Pharma plc...
...PFS), overall survival (OS) and time to next treatment Status: Phase II started Milestone: NA Julian Zhu SFX-01 sulforaphane Evgen Pharma plc...
BioCentury | Jan 12, 2017
Clinical News

SFX-01: Ph II SAS ongoing

...for up to 28 days plus nimodipine and has enrolled 26 of 90 planned patients. Evgen Pharma plc...
...and incidence of delayed cerebral ischemia Status: Phase II ongoing Milestone: Phase II data (1H18) Julian Zhu SFX-01 sulforaphane Evgen Pharma plc...
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...with topical vehicle. Next steps could include testing sulforaphane in other models of pachyonychia congenita. Evgen Pharma plc...
BioCentury | May 9, 2016
Clinical News

Sulforaphane: Phase II started

...90 patients. SFX-01 is administered as capsules or as a suspension via a nasogastric tube. Evgen Pharma plc...
BioCentury | Dec 21, 2015
Company News

Spanish National Research Council, University of Seville, Evgen Pharma deal

...for publication. Spanish National Research Council , Madrid, Spain University of Seville , Seville, Spain Evgen Pharma plc...
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Anterios Inc. 3/31/15 $50.7M Ph II RainDance Technologies Inc. 2/27/15 Up to $60M Mkt (tools) Evgen Pharma plc...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Inc. 2/2/15 $76M Ph III HTG Molecular Diagnostics Inc. 12/30/14 Up to $60M Mkt (diagnostic) Evgen Pharma plc...
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...12/22/14 Up to $69M Mkt (diagnostic) Ascendis Pharma A/S 12/18/14 Up to $86.3M Ph II Evgen Pharma plc...
BioCentury | Dec 8, 2014
Financial News

Evgen Pharma proposes IPO

Evgen Pharma plc , Liverpool, U.K. Business: Cancer, Neurology Date announced: 2014-12-04 Type: IPO To be raised: Up to £20 million ($31.3 million) Shares: TBD Price: TBD Note: Evgen is seeking to list its shares on...
Items per page:
1 - 10 of 11
BioCentury | May 9, 2018
Distillery Therapeutics

Dermatology

...in mouse models of other types of palmoplantar keratoderma and other diseases involving hyperproliferative keratinocytes. Evgen Pharma plc...
BioCentury | Jan 18, 2017
Clinical News

SFX-01: Ph II STEM started

...tamoxifen or a third-generation aromatase inhibitor in about 60 patients with evidence of disease progression. Evgen Pharma plc...
...PFS), overall survival (OS) and time to next treatment Status: Phase II started Milestone: NA Julian Zhu SFX-01 sulforaphane Evgen Pharma plc...
BioCentury | Jan 12, 2017
Clinical News

SFX-01: Ph II SAS ongoing

...for up to 28 days plus nimodipine and has enrolled 26 of 90 planned patients. Evgen Pharma plc...
...and incidence of delayed cerebral ischemia Status: Phase II ongoing Milestone: Phase II data (1H18) Julian Zhu SFX-01 sulforaphane Evgen Pharma plc...
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...with topical vehicle. Next steps could include testing sulforaphane in other models of pachyonychia congenita. Evgen Pharma plc...
BioCentury | May 9, 2016
Clinical News

Sulforaphane: Phase II started

...90 patients. SFX-01 is administered as capsules or as a suspension via a nasogastric tube. Evgen Pharma plc...
BioCentury | Dec 21, 2015
Company News

Spanish National Research Council, University of Seville, Evgen Pharma deal

...for publication. Spanish National Research Council , Madrid, Spain University of Seville , Seville, Spain Evgen Pharma plc...
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Anterios Inc. 3/31/15 $50.7M Ph II RainDance Technologies Inc. 2/27/15 Up to $60M Mkt (tools) Evgen Pharma plc...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Inc. 2/2/15 $76M Ph III HTG Molecular Diagnostics Inc. 12/30/14 Up to $60M Mkt (diagnostic) Evgen Pharma plc...
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...12/22/14 Up to $69M Mkt (diagnostic) Ascendis Pharma A/S 12/18/14 Up to $86.3M Ph II Evgen Pharma plc...
BioCentury | Dec 8, 2014
Financial News

Evgen Pharma proposes IPO

Evgen Pharma plc , Liverpool, U.K. Business: Cancer, Neurology Date announced: 2014-12-04 Type: IPO To be raised: Up to £20 million ($31.3 million) Shares: TBD Price: TBD Note: Evgen is seeking to list its shares on...
Items per page:
1 - 10 of 11